Efficacy and safety of nirmatrelvir/ritonavir (Paxlovid) for COVID‐19: a rapid review and meta‐analysis
This study aimed to examine the efficacy and safety of nirmatrelvir/ritonavir (Paxlovid) for
coronavirus disease 2019 (COVID‐19). PubMed, Cochrane Library, Web of Science …
coronavirus disease 2019 (COVID‐19). PubMed, Cochrane Library, Web of Science …
[HTML][HTML] Paxlovid (Nirmatrelvir/Ritonavir): A new approach to Covid-19 therapy?
Despite the need for novel, effective therapeutics for the COVID-19 pandemic, no curative
regimen is yet available, therefore patients are forced to rely on supportive and nonspecific …
regimen is yet available, therefore patients are forced to rely on supportive and nonspecific …
An overview on the treatments and prevention against COVID-19
Y Panahi, AM Gorabi, S Talaei, F Beiraghdar… - Virology Journal, 2023 - Springer
Background The coronavirus disease 2019 (COVID-19) caused by the severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to plague the world. While …
respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to plague the world. While …
Nirmatrelvir–ritonavir compared with other antiviral drugs for the treatment of COVID‐19 patients: A systematic review and meta‐analysis
F Tian, Z Chen, Q Feng - Journal of Medical Virology, 2023 - Wiley Online Library
At present, there are some differences in the research results of nirmatrelvir–ritonavir
compared with other antiviral drugs for the treatment of COVID‐19 patients. We aimed to …
compared with other antiviral drugs for the treatment of COVID‐19 patients. We aimed to …
Nirmatrelvir–ritonavir for the treatment of COVID‐19 patients: A systematic review and meta‐analysis.
The landscape of development of treatment modalities and preventive measures for COVID-
19 has progressed expeditiously since the beginning of the pandemic. We included all the …
19 has progressed expeditiously since the beginning of the pandemic. We included all the …
Real‐world effectiveness of Azvudine versus nirmatrelvir–ritonavir in hospitalized patients with COVID‐19: A retrospective cohort study
G Deng, D Li, Y Sun, L Jin, Q Zhou… - Journal of Medical …, 2023 - Wiley Online Library
Chinese guidelines prioritize the use of Azvudine and nirmatrelvir–ritonavir in COVID‐19
patients. Nevertheless, the real‐world effectiveness of Azvudine versus nirmatrelvir–ritonavir …
patients. Nevertheless, the real‐world effectiveness of Azvudine versus nirmatrelvir–ritonavir …
Drugs for COVID-19: An update
J Ceramella, D Iacopetta, MS Sinicropi, I Andreu… - Molecules, 2022 - mdpi.com
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was the seventh
known human coronavirus, and it was identified in Wuhan, Hubei province, China, in 2020. It …
known human coronavirus, and it was identified in Wuhan, Hubei province, China, in 2020. It …
[HTML][HTML] Antiviral effect of azvudine and nirmatrelvir-ritonavir among hospitalized patients with COVID-19
Y Gao, Z Luo, S Ren, Z Duan, Y Han, H Liu… - The Journal of …, 2023 - ncbi.nlm.nih.gov
We read with great interest the recent article in the Journal of Infection by Gentry et al., 1
which analyzed the clinical outcomes between those who received oral antivirals or not …
which analyzed the clinical outcomes between those who received oral antivirals or not …
[HTML][HTML] No evidence of clinical efficacy of famotidine for the treatment of COVID-19: a systematic review and meta-analysis
We read with great interest the recent article by Qian et al. that reported paxlovid as an
efficacious treatment for COVID-19 patients. 1 However, the relatively high cost of paxlovid …
efficacious treatment for COVID-19 patients. 1 However, the relatively high cost of paxlovid …
The antiviral effect of nirmatrelvir/ritonavir during COVID-19 pandemic real-world data
Introduction: Vaccination against SARS-CoV-2 and the prevalence of Omicron variants have
reduced the risk of the severe clinical progress of COVID-19. However, the risk of …
reduced the risk of the severe clinical progress of COVID-19. However, the risk of …